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Background: Stable angina pectoris is experienced as trans-sternal or retro-sternal pressure or pain that may radiate
to the left arm, neck or back. Although available evidence relating to its effectiveness and mechanism are weak,
traditional Chinese medicine is used as an alternative therapy for stable angina pectoris. We report a protocol of a
randomized controlled trial using traditional Chinese medicine to investigate the effectiveness, mechanism and
safety for patients with stable angina pectoris.
Methods/Design: This is a north-east Chinese, multi-center, multi-blinded, placebo-controlled and superiority
randomized trail. A total of 240 patients with stable angina pectoris will be randomly assigned to three groups: two
treatment groups and a control group. The treatment groups will receive Chinese herbal medicine consisting of
Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granule and Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu granule, respectively, and conventional
medicine. The control group will receive placebo medicine in addition to conventional medicine. All 3 groups will
undergo a 12-week treatment and 2-week follow-up. Four visits in sum will be scheduled for each subject: 1 visit each
in week 0, week 4, week 12 and week 14. The primary outcomes include: the frequency of angina pectoris attack;
the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire. The secondary outcomes
include: except for the body limited dimension of SAQ, traditional Chinese medicine pattern questionnaire and so
on. Therapeutic mechanism outcomes, safety outcomes and endpoint outcomes will be also assessed.
Discussion: The primary aim of this trial is to develop a standard protocol to utilize high-quality EBM evidence for
assessing the effectiveness and safety of SAP via TCM pattern differentiation as well as exploring the efficacy
mechanism and regulation with the molecular biology and systems biology.
Trial registration: Clinical Trials Registration: ChiCTR-TRC-13003608, registered 18 June 2013.Background
Stable angina pectoris (SAP) due to coronary heart dis-
ease (CHD) is defined as a major clinical manifestation
of trans-sternal or retro-sternal pressure or a choking
sensation or pain, which is caused by coronary insuffi-
ciency, myocardial ischemia, and hypoxia on the basis of
an atherosclerotic coronary vascular lumen [1,2]. Ac-
cording to World Health Organization (WHO), CHD is
one of the major causes of death and has drawn the* Correspondence: yangguanlin945@gmail.com
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unless otherwise stated.attention of traditional Chinese medicine (TCM) and
western medicine (WM) researchers. In China, the preva-
lence and incidence of SAP are 2.4% in males and 3.2% in
females, which is a serious social problem in view of its
large population basis [3]. Its treatment is mainly relief of
symptoms with anti-anginal medications or revasculariza-
tion procedures. The anti-anginal medications are selected
from three groups of anti-anginal chemical drugs includ-
ing β blockers (BBs), calcium channel blockers (CCBs)
and nitrates [4]. In China, a large majority of SAP patients
resort to Chinese herbal medicine, acupuncture and other
TCM therapies [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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TCM pattern elements. The relationship between spleen
deficiency generating phlegm and SAP has been recorded
in the Inner Canon of the Yellow Emperor (Huangdi
Neijing). Correspondingly, phlegm and spleen deficient
is one of the main TCM patterns of SAP in terms of re-
cent studies [6,7].
The TCM pattern is a characteristic profile of clinical
signs and symptoms manifested by a group of patients
[4]. Wang Yong-yan, Academician of Chinese Academy
of Engineering, postulated that TCM pattern had the
performance characteristics that included reality inside and
virtual outside, spatiotemporal dynamic, multi-dimensional
interface [8] . Lu Guang-xin, TCM master, announced that
the TCM pattern was the core concept and logical starting
point of pattern differentiation, which contained the
property of diagnostics, pathophysiology, and therapeu-
tics [9,10]. Hence, we may believe that TCM pattern is a
physiological regulation network, which contains a regula-
tion center, overall effective target, material basis and func-
tional unit. Its mechanism needs to be indicated by means
of TCM pattern prevention and treatment characteristics,
multiple organ integration effectiveness, and functional
unit network so as to guide clinical practice as well as for
inspiring basic research.
Systems biology, defined as multiple comics integration
and consolidation from genes, cells, the organization of in-
dividuals, is the TCM pattern efficacy and mechanism re-
search method fitting with TCM theory, characteristics
and discipline [11-13]. Hence, we utilize high throughput
screening (HTS) technology of systems biology; that is
transcriptomics, metabonomics, proteomics, and so on, to
promote fundamental research of TCM pattern, global
Chinese compound medicine selection, evaluation and
technology platform. In recent years, a comprehensive ap-
proach has shown the TCM efficacy mechanism of SAP in
the view of regulating lipid metabolism abnormality and
resisting inflammatory expression and endothelial dys-
function [14]. However, there is not adequate understand-
ing of the interaction and relationship between spleen
deficiency generating phlegm of SAP (response system)
and regulation from spleen (intervention system) through
the scattered and small-scale reduction biological research.
Notably, we should explore the clinical evaluation and effi-
cacy mechanism and regulation on the foundation of sys-
tems biology and evidence-based medicine (EBM).
In this trial, we intend to investigate the efficacy mech-
anism for SAP with spleen deficiency and phlegm pattern
through brain-gut axis regulation of lipid metabolism,
immune inflammation and vascular endothelial network.
Meanwhile, we attempt to further validate the effective-
ness and safety in light of clinical efficacy evaluation index,
which is the frequency and duration of angina pectoris at-
tacks, health-related quality of life, and so on.Methods/Design
Study design
This is a north-east Chinese, multi-center, multi-blinded,
placebo-controlled and superiority randomized trail with
three parallel groups. The study protocol was based on
strict and scientific recommendations in the Consolidated
Standards of Reporting Trials (CONSORT) statement [15]
and SPIRIT 2013 Statement [16]. This trial was supported
financially by the National Basic Research Program of
China ‘973 Program’ (Number 2013CB531704). The trial
was registered in Chinese ClinicalTrials.gov with approval
number ChiCTR-TRC-13003608.
Two hundred and forty participants will be recruited
at six large comprehensive hospitals in China, which are:
Affiliated Hospital of Liaoning University of TCM, Liaoning
Institute of Chinese Medicine, Affiliated Hospital of
Inner Mongolia National University, Shen-Zhou Hospital
of Shenyang Medical College, First Affiliated Hospital of
China Medical University, and Sheng-Jing Hospital of
China Medical University. After a two-week run-in period,
eligible subjects will be randomly assigned to one of 3
groups, Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo group
(Group 1), Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu group
(Group 2), and the placebo group. All three groups then
underwent a 12-week treatment and a 2-week follow-up
period. The flow chart is listed in Figure 1.
Randomization and allocation concealment
A total of 240 patients will be randomly assigned in a ra-
tio of 1:1:1 using the statistical package. To guarantee
rigorous methodology, stratified block randomization and
central coordination will be initiated. The unique code will
be assigned to each newly eligible participant and properly
preserved in the trial management board. This procedure
ensures each eligible patient having an equal probability of
being assigned to three different groups, which will not be
influenced by the researchers. A statistician expert of the
Beijing Bozhiyin Science and Technology Co. Ltd, Beijing,
China will act as the coder and they will be shielded from
patient recruitment.
Blinding
This trial is a multi-blinded design and researchers, par-
ticipants, drug management staff, data collection staff
and statisticians will be blinded during the trial period.
When an emergency occurs (such as a serious adverse
events), or doctors must know the treatment of patients
who require intervention, the researcher should immedi-
ately inform the main researcher to unblind the central
random system. Moreover, the main researchers and trial
monitors will be informed immediately. Once the blind
letter is open following an emergency, the participant will
be eliminated from the trial and the researcher should
note the reason, blind time and place of uncovering in the
Patients Screened˄n=˅
Excluded  (n=  )
•  Not meeting inclusion criteria (n=  )
•  Declined to participate (n=  )
•  Other reasons (n=  )
Randomized 1:1:1(n=240)
Allocated to group 1 (n=  ) 
• Received allocated intervention (n=  )
• Did not receive allocated intervention
  (give  reasons) (n=  ) 
Allocated to group 2 (n=  ) 
• Received allocated intervention (n=  )
• Did not receive allocated intervention
  (give  reasons) (n=  ) 
Allocated to control (n=  ) 
• Received allocated intervention (n=  )
• Did not receive allocated intervention
  (give  reasons) (n=  ) 
Intervention(12 weeks)
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) 
(n=  ) 
Follow-up(2weeks)
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) 
(n=  ) 
Lost to follow-up (give reasons) (n=  ) 
Discontinued intervention (give reasons) 
(n=  ) 
Analysed  (n=  )  
•  Excluded from analysis (give reasons) 
(n=    ) 
Analysis
Analysed  (n=  )  
•  Excluded from analysis (give reasons) 
(n=    ) 
Analysed  (n=  )  
•  Excluded from analysis (give reasons) 
(n=    ) 
Run-in period(2 weeks)
Figure 1 Trial flow chart.
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searcher, Institutional Review Board (IRB) and staff who
perform the unblinding.
Participants
The study will enroll 240 patients, which fulfill the fol-
lowing items of criteria in this trail.
Diagnostic criteria
(1) WM diagnostic criteria of diagnosis and treatment
guidelines for chronic stable angina pectoris
according to the Chinese Society of Cardiology in
2007 [17]
(2) TCM diagnostic criteria of Chinese Internal
Medicine according to the 11th Five-Year national
programmed textbooks together with expert
demonstration. The signs and symptoms as follows:
chest distress superior and pain inferior, excessive
phlegm, shortness of breath, heavy limbs, obesity,
attack or aggravation on a rainy day, exhaustion,
loss of appetite, loose stool, expectoration, plump
tongue and side tooth marks, greasy and glossy
coating, slippery pulseInclusion criteria
(1) Diagnosis of CHD with SAP as well as spleen
deficiency and phlegm pattern according to WM
and TCM
(2) Age: male: 45 to 75 years old (including 45 and
75 years old); female: 50 to 75 years old (including
50 and 75 years old)
(3) Main coronary artery stenosis between 50%
and 75% or branch coronary artery stenosis
between 50% and 100% in the previous
3 months as shown on coronary angiogram or
coronary computed tomography (CT)
examination report
(4) Patients meet Class II to IV of the Canadian
Cardiovascular Society (CCS) angina pectoris
severity grade
(5) Able to understand and sign a written informed
consent
Exclusion criteria
(1) Pattern differentiation except for spleen deficiency
and phlegm pattern
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angina pectoris (UAP), hypertrophic cardiomyopathy
(HCM), neurosis, post-menopausal pattern, gastric
and esophageal reflux disease (GERD), and so on
(3) Main coronary artery (right coronary artery (RCA),
left main stem (LM), left anterior descending
(LAD), left circumflex (LCX)) more than 75%
stenosis according to coronary angiogram or
coronary CT
(4) Acute myocardial infarction in the previous half year
or completely revascularization history within a year
(5) Severe heart failure (class IV of heart function),
malignant arrhythmia, hypertension higher than
160/100 mmHg within standard anti-hypertensive
therapy, other serious system diseases (malignant
tumor, gastrointestinal hemorrhage, gastric ulcer,
and so on) and function examination of liver and
kidney (more than 1.5 times the reference value of
aspartate aminotransferase (AST), alanine trans-
aminase (ALT), creatinine (Cr))
(6) Mental disorder
(7) Pregnancy, planned pregnancy and breast-feeding
women
(8) Chinese medicine granule and iodine allergy
(9) Glaucoma patients
(10) A history of another clinical trial in the previous
2 months
(11) No consent form signed
Handling of withdrawal and dropout
(1) Voluntarily withdrawal
(2) Loss of follow-up
(3) Poor compliance and presence of severe adverse
effects
(4) Revealing and uncovering blind in urgency
(5) Misdiagnosis
(6) Using forbidden drugs or treatments in the course
of the trial
(7) Taking no medication during the trial
(8) No evaluable records after medication
Reasons for withdrawing participants will be recorded
in CRFs, and the last data would be included in data
analysis.
The whole research plan would be terminated for the
following circumstances:
(1) Occurrence of serious adverse events related to the
research medication
(2) Flawed protocol
(3) Funding and management problem due to the
sponsors
(4) Administrative authorities terminate the trialRecruitment strategies
We will apply two strategies to recruit participants with
angina pectoris. Firstly, we will recruit participants from
out-patient clinics and in-patient department in every
clinical center. Secondly, potential patients in local com-
munities and out-hospital clinics will be recruited by
advertisements in the post, leaflets, TV broadcast and
newspapers. The posters will contain brief introductions
about the population needed to be involved, the free
treatments offered to eligible participants and the con-
tact information of the researcher. Participants will be
included if they meet the inclusion criteria and have pro-
vided written informed consent indicating that they
agree to this trial and join in the trial voluntarily.
Intervention
TCM intervention
Participants randomized to treatment Group 1 will take
Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granule, which is
composed of HuangQi (Astragalus membranaceus) - 10 g,
DangShen (Codonopsis pilosula) - 10 g, BaiZhu (Atracty-
lodes macrocephala Koidz) - 10 g, FuLing (Poria cocos
Wolf) - 10 g, QingBanXia (Rhizoma pinelliae Preparata) -
6 g, GuaLou (Trichosanthes kirilowii Maxim) - 10 g,
DanShen (Salvia miltiorrhiza) - 10 g, ZhiGanCao (Glycyr-
rhiza uralensis Fisch) - 3 g. Those in treatment Group 2
(Yi-Qi-Jian-Pi and Qu-Tan-Hua-Yu granule) are composed
of DanShen (Salvia miltiorrhiza) - 10 g, BaiZhu (Atracty-
lodes macrocephala Koidz) - 10 g, FuLing (Poria cocos
Wolf) - 10 g, ZhiGanCao (Glycyrrhiza uralensis Fisch) -
3 g, QingBanXia (Rhizoma pinelliae Preparata) - 6 g,
GuaLou (Trichosanthes kirilowii Maxim) - 10 g, TaoReng
(Prunus persica Batsch) - 10 g, HongHua (Carthamus
tinctorius) - 6 g. The action and batch number of each
herb is summarized in Table 1 [7]. The control group is
made from Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo granules
(10%) and starch (90%) to achieve the same shape, color,
smell, taste, texture package and Lot Number. Patients
are instructed to dissolve granules into 100 ml of hot
water and to take the solution orally between 30°C to
37°C twice daily for 12 weeks. Each granule is prepared
by Jiangyin Tianjiang Pharmaceuticals Co. Ltd, Jiangsu,
China according to the standards of Good Manufactory
Practice (GMP) [18].
WM conventional intervention
An anti-anginal drug, nitroglycerin, is selected as WM
conventional treatment and allowed to be taken at a dose
of 0.5 g sub-lingual at at least 5-minute intervals [19].
Concomitant treatments and forbidden drugs
(1) Patients are not allowed to take any other TCM
intervention (acupuncture treatment, angina
Table 1 The action and batch number of each herb
Ingredients Lot number Action
HuangQi (Astragalus membranaceus) 1302026 TCM: tonifying spleen and protecting defensive Qi.
Pharmaceutical study: 1. Promoting metabolism effect. 2. Diuresis effect. 3. Cardiovascular
system protecting effect.
DangShen (Codonopsis pilosula) 1302095 TCM: tonifying Qi of spleen and lung and benefiting blood and body fluid.
Pharmaceutical study: 1. Adjusting gastrointestinal movement effect. 2. Anti-ulcer effect.
3. Immune-enhancing effect. 4. Anti-aging effect.
BaiZhu (Atractylodes macrocephala Koidz) 1302011 TCM: tonifying Qi of spleen, eliminating dampness and diuresis.
Pharmaceutical study: 1. Intestinal tube two-way regulation effect. 2. Anti-ulcer
effect. 3. Diuresis effect. 4. Strong effect.
FuLing (Poria cocos Wolf) 1301056 TCM: diuresis, detumescence, tonifying Qi of spleen and tranquilization.
Pharmaceutical study: 1. Diuresis effect. 2. Calming effect. 3. Anti-tumor effect.
4. Anti-diabetic effect. 5. Enhance myocardial contractility.
QingBanXia (Rhizoma pinelliae Preparata) 1301078 TCM: eliminating dampness, resolving phlegm, controlling vomiting and eliminating
stagnation.
Pharmaceutical study: 1. Vomiting control effect. 2. Anti-tumor effect. 3. Gastric
secretion inhibition effect.
GuaLou (Trichosanthes kirilowii Maxim) 1301157 TCM: clearing heat, reducing phlegm, eliminating stagnation and relaxing bowels.
Pharmaceutical study: 1. Reducing phlegm effect. 2. Coronary artery dilatation effect.
3. Lipid-lowering effect.
DanShen (Salvia miltiorrhiza) 1301173 TCM: activating and cooling blood, regulating menstruation, removing stasis and pain.
Pharmaceutical study: 1. Improving myocardial ischemia effect. 2. Improving
microcirculation effect. 3. Hypotensive effect. 4. Platelet aggregation inhibition effect.
5. Liver protection effect. 6. Anti-inflammatory effect.
ZhiGanCao (Glycyrrhiza uralensis Fisch) 1212045 TCM: tonifying Qi of spleen, eliminating phlegm, anti-cough, heat-clearing and
detoxifying and reconciling.
Pharmaceutical study: 1. Anti-arrhythmia effect.2. Anti-ulcer effect.3.Diuresis effect.
4. Analgesia effect. 5. Anti-tussive effect. 6. Eliminating phlegm effect.
TaoReng (Prunus persica Batsch) 1212013 TCM: activating blood, removing stasis, relaxing bowels and relieving cough and asthma.
Pharmaceutical study: 1. Cerebral blood flow improving effect. 2. Anti-coagulant effect.
3. Analgesia effect. 4. Anti-allergic effect. 5. Relieving cough and asthma effect.
HongHua (Carthamus tinctorius) 1212080 TCM: activating blood, regulating menstruation, removing stasis and pain.
Pharmaceutical study: 1. Improving myocardial ischemia and coronary artery flow effect.
2. Anti-arrhythmia effect. 3. Hypotensive effect. 4. Platelet aggregation inhibition effect.
5. Analgesia and sedation effect. 6. Anti-inflammatory effect.
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nitroglycerin, non-dihydropyridine CCBs and
lipid-lowering drugs
(2) In the run-in and study period, usage of aspirin, BBs
and dihydropyridine CCBs in the previous 4 weeks is
allowed to continue and conversion is prohibited
(3) The dosage, duration and name of any
concomitant treatment or medication must be
recorded carefully in the CRFs
Drug management
Seventy-five to 120% of drug usages are eligible for proto-
col plan. The three groups’ granules will be prepared re-
spectively but uniformly packaged. The package, drug
name, function and indication, usage and dosage, storage
condition, valid period and name of the manufacturer will
be marked and a tag indicating ‘trial use’ will be attached.Drugs must be kept in the appropriate temperature in a
dry, shady and cool place. Drug administrators should re-
turn unused drugs to estimate participant compliance and
note these in the CRFs.
Outcomes
Efficacy outcomes
The primary outcomes include:
(1) Frequency of angina pectoris attacks
(2) Dosage of nitroglycerin
(3) Body limited dimension of Seattle Angina
Questionnaire (SAQ)
The secondary outcomes include:
(1) SAQ except for the body limited dimension
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(3) The duration of angina pectoris
(4) Angina pain severityTherapeutic mechanism outcomes
Blood serum metabolites; total cholesterol (TC); triglyc-
erides (TG); low-density lipoprotein (LDL); high-density
lipoprotein (HDL); ox-LDL; hypersensitive C reactive pro-
tein; homocysteine; glucagon like peptide-1; angiotonin II;
HMG-COA reductase; adherence factor PS; scavenger
receptor A; scavenger receptor B; chemokine MCP-1; ad-
herence factor vascular cell adhesion protein (VCAM)-1;
5-HT; vasointestinal peptide (VIP); ghrelin; norepineph-
rine (NE); acetylcholine (Ach); mtDNA copy number;
MicroRNA155; MicroRNA 33; MicroRNA 126; Micro-
RNA 125; MicroRNA 221; MicroRNA 222.Safety outcomes
For the sake of participant safety, the following biological
indicators will be monitored and watched throughout the
trial: blood routine, liver function (AST, ALT), renal func-
tion (BUN, Cr), and electrocardiograph (ECG). Adverse
events are defined as any unexpected or uncomfortable
signs, symptoms, or diseases. Once adverse events happen
during the treatment and follow-up period, all the details
should be documented in the CRF form and reported to
the ethics committee immediately so that they can make a
decision about whether the patient should withdraw from
the trial.Endpoint outcomes
Death incident: cardiovascular death, cerebrovascular
death, sudden death, other cause of death.
Cardiovascular incident: unstable angina pectoris
hospitalization, acute myocardial infarction, malignant
arrhythmia, cardiac shock, revascularization and other
cardiovascular incident.
Non-cardiovascular incident: stroke, pulmonary embol-
ism, peripheral vessel, tumor, other non-cardiovascular
incident.
All three groups will undergo a twelve-week treatment
and two-week follow-up. Four visits in sum will be sched-
uled for each subject: one visit each in week 0, week 4,
week 12 and week 14. The CRFs contains a range of infor-
mation and this will be completed by the corresponding
researchers at each center. Trial coordinators and thera-
pists at each center will record above endpoint outcome
and the details of these events throughout the treatment
and follow-up period. Outcomes to be measured and the
time points of data collection can be found in Additional
file 1: Table S1.Quality control
Quality control will be conducted by rigorous monitor-
ing throughout the trial. All staff who enroll participants,
assessors who collect data and management who distrib-
ute drugs must attend training to make sure all practices
at each hospital are generalized and standardized according
to the standard operating procedures (SOP). Physicians
must pass the required training test to understand the pur-
pose and content of the trial, intervention strategies and
any adverse events observation. To guarantee compliance,
researchers must remind the participants of the regular
visits ahead of 2 or 3 days.
Sample size calculation
According to the response rates of treatment, Group 1
and placebo were 88.5% and 60%, respectively; 37 patients
of each group was estimated as sufficient to achieve 80%
power in detecting treatment differences, based on two-
sided Chi-square test without continuity correction at a
significance level of 0.05 (α = 0.05; 1-β = 0.80). In the
same way, assuming the clinical effective rates of Group 2
and placebo were 82.5% and 60%, respectively and 64 pa-
tients of each group was estimated as sufficient to achieve
80% power. Meanwhile, taking into account a dropout of
15%, we concluded that a total of 240 patients with 80 for
each group would need to be recruited to ensure statisti-
cally significant results.
Statistical analysis
The statistical analysis will be conducted by a statistician
of the Beijing Bozhiyin Science and Technology Co. Ltd,
China. They are blinded to the whole trial and using
Statistical Analysis System (SAS, Cary, NC, USA) version
9.2 and Statistic Package for Social Science (SPSS, Chicago,
IL, USA) version 17.0 software packages. All mechanism,
efficacy and safety analyses will be strictly conducted ac-
cording to the intention-to-treat (ITT) principle and the
full analysis set (FAS) population, the per-protocol set
(PPS) population and the safety set (SS) population. Miss-
ing values will be replaced by the last observation carried
forward (LOCF) method.
The statistical significance is defined as a two-sided
P-value of <0.05 and 95% confidence interval. For de-
scriptive statistics, continuous variables will be described
as numerous, mean ± standard deviation, median, Q1 to
Q3 and mini-maxi and dichotomous data will be reported
as frequency and percentage. Baseline differences among
the groups will be assessed with the use of Student’s t-test
for normally distributed continuous variables and the
non-parametric Mann-Whitney U-test for non-normally
distributed variables. Comparisons between groups will be
conducted by using an analysis of covariance (ANCOVA)
with baseline as covariate. For efficacy analysis, changes
from baseline to endpoint of treatment in scores will
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(ANOVA). Within group differences will be assessed
with paired t-test for normally distributed data and
Wilcoxon signed-rank test for non-normally distributed
data. Mechanism will be assessed between mechanism
index and primary outcomes by ANCOVA and regres-
sion analysis. Safety will be assessed by participant com-
pliance and adverse events. The endpoint events will be
listed by detailed account.
Ethics issue and informed consent
This trial is in accordance with the principles of the
Declaration of Helsinki (version Edinburgh 2000). The study
protocol was reviewed and approved by IRB of the Affiliated
Hospital of Liaoning University of TCM (Number 2013CS
(KT)-002-01), IRB of the Liaoning Institute of Chinese
Medicine (Number 20130509-1), IRB of the Affiliated
Hospital of Inner Mongolia National University, IRB of
the Shen-Zhou Hospital of Shenyang Medical College,
IRB of the First Affiliated Hospital of China Medical
University and IRB of the Sheng-Jing Hospital of China
Medical University. Before randomization, all eligible pa-
tients are informed of the details of the study and all the
benefits and risk that they may take from this trial. Mean-
while, we require all patients to sign the written informed
consent prior to enrollment, and they are given enough
time to decide whether they will take part in this trial.
Discussion
SAP is a major public health problem, which can endanger
a patient’s life quality. Currently, TCM has a considerable
role in the symptom and quality of life improvement of
SAP patients in China and worldwide.
Our research team has conducted a deep study of the
pathogenesis, TCM pattern feature and efficacy evaluation
of TCM in SAP. We proposed that the key pathogenic
mechanism was phlegm and blood stasis integration owing
to spleen deficiency generating phlegm and phlegm leading
to blood stasis [20]. Otherwise, we have developed pattern
differentiation standard of SAP and TCM pattern diagnosis
and efficacy evaluation scale for pattern of phlegm and
blood stasis integration [21,22].
To our knowledge, this may be the first trial to utilize
high-quality EBM evidence to assess the effectiveness and
safety of SAP via TCM pattern differentiation, as well as
exploring the efficacy mechanism and regulation with the
molecular biology and systems biology. In the present
study, we establish two treatment groups and one control
group in this trial. Our aim of establishing these three
groups is to differentiate and isolate the placebo effect and
research bias; in particular, to further appropriately valid-
ate the accumulation effect of activating blood and remov-
ing stasis on the basis of tonifying spleen and eliminating
phlegm. It is worth mentioning that we tried to contactthe central regulation with the effect organ through
multiple communication pathways, such as brain-gut axis
regulation of lipid metabolism, immune inflammation,
and vascular endothelial network, so as to explain the spe-
cific process of the efficacy mechanism and regulation of
SAP from spleen.
We have presented the design and protocol for a ran-
domized controlled trial of patients with SAP together
with spleen deficiency and phlegm pattern. The clinical
trial protocol plays a vital role of study conduct, report-
ing, and appraisal. To facilitate appropriate high quality
methodology and strict quality control, this protocol has
been developed according to the CONSORT statement,
SPIRIT 2013, and SPIRIT 2013 explanation and elabor-
ation [23]. We particularly described our method of re-
cruitment, randomization and allocation concealment, and
data collection. In addition, we reported the TCM inter-
vention according to Recommendations for Reporting
Randomized Controlled Trials of Herbal Interventions, in-
cluding dosage, action, batch number, and quantitative de-
scription. Completion of this trial may highlight evidence
on the effectiveness and safety of TCM and provide the ap-
proaches on the efficacy mechanism and regulation of
TCM pattern. The results of this study may generate scien-
tific and rigorous evidence for the study of SAP via TCM
pattern differentiation.Trial status
At the time of manuscript submission, patient recruitment
for the trial is on-going.Additional file
Additional file 1: Table S1. Schedule of enrollment, intervention and
assessments.Abbreviations
Ach: acetylcholine; ALT: alanine transaminase; ANCOVA: analysis of
covariance; ANOVA: analysis of variance; AST: aspartate aminotransferase;
BBs: β blockers; BUN: blood urea and nitrogen; CCBs: calcium channel
blockers; CCS: Canadian Cardiovascular Society; CHD: coronary heart disease;
CONSORT: Consolidated Standards of Reporting Trials; Cr: creatinine;
CRFs: Case Report Forms; CT: computed tomography; EBM: evidence-based
medicine; ECG: electrocardiograph; FAS: full analysis set; GERD: gastric and
esophageal reflux disease; GMP: Good Manufactory Practice; Group 1:
Yi-Qi-Jian-Pi and Qu-Tan-Hua-Zhuo group; Group 2: Yi-Qi-Jian-Pi and
Qu-Tan-Hua-Yu group; HCM: hypertrophic cardiomyopathy; HDL: high-density
lipoprotein; HTS: high throughput screening; IRB: Institutional Review Board;
ITT: intention-to-treat; LAD: left anterior descending; LCX: left circumflex;
LDL: low-density lipoprotein; LM: left main stem; LOCF: last observation
carried forward; NE: norepinephrine; PPS: per-protocol set; RCA: right
coronary artery; SAP: stable angina pectoris; SAQ: Seattle Angina
Questionnaire; SAS: Statistical Analysis System; SOP: standard operating
procedures; SPSS: Statistic Package for Social Science; SS: safety set; TC:
total cholesterol; TCM: traditional Chinese medicine; TG: triglycerides;
UAP: unstable angina pectoris; VCAM-1: vascular cell adhesion protein-1;
VIP: vasointestinal peptide; WHO: World Health Organization; WM: western
medicine.
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